Mechanism
BPC-157 exerts its effects through multiple intersecting pathways, which is both what makes it broadly interesting in animal models and what makes it difficult to study systematically.
| Mechanism | Detail |
|---|---|
| Nitric oxide system | Stimulates nitric oxide (NO) synthesis, which promotes vasodilation and angiogenesis. Considered one of BPC-157's primary healing mechanisms in animal wound and tendon models. |
| Growth hormone receptor upregulation | Upregulates GH receptors in tendon fibroblasts. Animal studies show accelerated collagen synthesis as a downstream effect. Potentially relevant to soft tissue repair. |
| Dopamine & serotonin modulation | Interacts with dopaminergic and serotonergic pathways. Animal research shows neuroprotective and mood-modifying effects. Basis for CNS-related animal studies. |
| Cytoprotective (GI) | Derived from gastric juice protein; exhibits gastroprotective effects in rodent models of ulcer, colitis, and intestinal injury. Among the best-replicated findings in the literature. |
| VEGFR2 / FAK / paxillin signaling | Cell-culture evidence: modulates VEGF receptor and cell adhesion signaling. Supports the angiogenesis and wound healing data seen in animal studies. |
Evidence Summary
BPC-157 has one of the largest preclinical bodies of evidence of any RUO peptide. The key caveat: nearly all of it is rodent-based. The leap from rodent to human is unvalidated.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| GI / Gut health | Strong animal signal | Rodent — multiple labs | Ulcer prevention, IBD models, fistula repair. Most replicated finding. Original application area. |
| Tendon & ligament healing | Strong animal signal | Rodent — multiple studies | Achilles tendon, ligament rupture models. Accelerated healing vs control. Most-cited community application. |
| Bone healing | Moderate animal signal | Rodent | Fracture healing studies showing accelerated callus formation. Less consistent than tendon data. |
| CNS / Neuroprotection | Early animal | Rodent — TBI, stroke | Dopamine/serotonin modulation; some TBI and stroke studies show signal. Mechanistically plausible but limited. |
| Muscle repair | Limited animal | Rodent | Some muscle crush and transection studies. Less robust than tendon data. Often grouped with TB-500 in community use. |
| Cardiovascular | Limited animal | Rodent | Some cardioprotective data in animal models. Not a primary application area. |
| Human clinical trials | None published | — | No published human RCTs as of mid-2026. A Croatian trial has been registered but not published. All human application extrapolated from animal data. |
Divergence — What This Means
Community use is far ahead of the research.
BPC-157 is one of the most widely used research peptides in the community. It is also one of the most divergent: the doses, routes, and applications discussed in forums and social media have no direct human research basis. Community protocols are extrapolated from rodent mg/kg amounts using body-surface-area scaling — a method with significant uncertainty even in pharmaceutical development, let alone for unapproved peptides.
This does not mean the community is wrong. It means there is no data to confirm or refute their protocols. The divergence is a knowledge gap, not necessarily a safety signal.
This does not mean the community is wrong. It means there is no data to confirm or refute their protocols. The divergence is a knowledge gap, not necessarily a safety signal.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Common community range
200–500 mcg
Per administration
Community frequency
Once daily
Some split AM/PM
Routes discussed
SC or oral
Subcutaneous or sublingual
Cycle length discussed
4–12 weeks
No research basis for cycling
Basis for these figures: These ranges are drawn from community forums (r/Peptides, biohacking communities) and do not correspond to any published human clinical trial. Rodent studies use microgram-per-kg amounts administered IP or SQ; human equivalents derived from BSA scaling are highly speculative. These figures should not be used as dosing guidance.
Safety Profile
Animal toxicity studies have not flagged major acute safety concerns at research doses. The absence of human trial data means the human safety profile is unknown.
Animal / preclinical — signals observed
No significant toxicity in standard rodent studies at research doses
No organ toxicity observed in preclinical tox panels
No mutagenicity reported in available studies
Well-tolerated subcutaneously in animal models
What is not known (human)
Long-term safety in humans: no data
Drug interactions: not studied
Oncogenic potential in humans: unknown
Endocrine effects with repeated use: unknown
Bioavailability via oral route in humans: not established
Community-reported adverse effects include injection-site reactions, nausea (particularly at higher doses), and headache. These are anecdotal. No systematic adverse-event tracking exists for unapproved human use.
Regulatory Status — Updated July 2026
PCAC recommended BPC-157 for the 503A list
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend BPC-157 for the 503A bulks list — the substances compounding pharmacies are permitted to use. This is a move toward restoring a legal compounding pathway, not restricting one.
Two caveats: the recommendation is advisory, and the FDA still has to finalize it through rulemaking (typically months), so nothing has changed in law yet. It also does not change anything for RUO suppliers, who operate under separate statutes. Track current status →
Two caveats: the recommendation is advisory, and the FDA still has to finalize it through rulemaking (typically months), so nothing has changed in law yet. It also does not change anything for RUO suppliers, who operate under separate statutes. Track current status →
Where to Source
Source research-grade BPC-157
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source BPC-157.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
BPC-157 is a synthetic peptide derived from a region of Body Protection Compound, a protein naturally occurring in gastric juice. It was first described by Croatian researcher Predrag Sikiric and colleagues, who have published the majority of the preclinical literature on it.
No published human RCTs exist as of mid-2026. A clinical trial was registered in the NIH registry but results have not been published. All human application is extrapolated from rodent data — a significant limitation the community often understates.
They are often grouped but have distinct research profiles. BPC-157 has a broader evidence base across GI, tendon, and CNS models. TB-500 is a Thymosin Beta-4 fragment with stronger signals in muscle, wound healing, and cardiovascular tissue. See the full comparison: BPC-157 vs TB-500 →
The committee voted 8–6–1 to recommend BPC-157 for the 503A bulks list — a step toward letting compounding pharmacies use it again. The vote is advisory; the FDA still has to finalize it through rulemaking, so it is not yet in effect. See the regulatory tracker for the full result.
Divergence is the gap between how a compound is discussed in the community and what the research actually supports. For BPC-157, community dosing protocols are derived from rodent studies via body-surface-area scaling — not from human clinical data, which does not exist. That is what "high divergence" means on Peptide Atlas.
Compare BPC-157